Exelixis

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exelixis reports robust Q4 performance, eyes pipeline expansion in 2023

Exelixis showed strong revenue growth and strategic wins in Q4 2022.
The company faces challenges with net losses and gross to net expectations.
Opportunities lie in pipeline advancement, zanzalintinib development, and new business activities.
Overall, Exelixis remains focused on growth and innovation in the pharmaceutical sector.

Exelixis reports strong Q1 earnings, advances promising pipeline programs

Exelixis showcased robust financials and a promising pipeline in Q1, driven by strong CABOMETYX performance and R&D advancements.
Challenges include gross to net impact and delays in share repurchase program purchases, with key decisions pending on XL102 progress.
Opportunities lie in expanding Phase 3 trials, focusing on unmet needs, and maintaining a strategic approach to asset prioritization for future growth.

Exelixis reports robust Q2 earnings, advances pipeline for growth

Exelixis delivered a strong Q2 performance with significant revenue and income figures, driven by the success of CABOMETYX and ongoing R&D efforts.
The company's market leadership, legal resolution with Teva, and commitment to innovation position it well for future growth and competitive advantage.
While facing challenges in program decision-making and market penetration, Exelixis has opportunities in pipeline advancement, regulatory discussions, and investor engagement.
Overall, Exelixis remains focused on its mission to help cancer patients, with a positive outlook and strategic initiatives in place for continued success.

Exelixis reports strong Q3 earnings, faces guidance challenges and growth opportunities

Exelixis had a strong Q3 2023 with robust revenue growth from CABOMETYX and ongoing operational support.
The company faces challenges in financial guidance adjustments and questions on FDA expectations and legal proceedings.
Opportunities lie in potential growth for CABOMETYX, advancing pipeline assets, and expanding into new indications.
Overall, Exelixis remains focused on innovation, collaboration, and supporting cancer patients with upcoming R&D Day excitement.

Exelixis reports robust 2023 performance, eyes growth through collaborations

Exelixis had a strong financial performance in 2023, driven by the cabozantinib franchise and strategic initiatives.
While facing challenges such as access to therapies and treatment variations, the company is well-positioned for growth.
Opportunities lie in collaborations, regulatory progress, and innovative drug development, positioning Exelixis for future success.

Exelixis reports strong Q1 earnings, focuses on pipeline advancement

Exelixis had a robust Q1 2024 with revenue and demand growth for Cabozantinib franchise.
Company is focused on advancing new indications, returning capital to shareholders, and pipeline development.
Challenges include study criteria, market capture, and capital allocation decisions.
Exciting opportunities lie in Zanza's potential, new combinations, and market growth prospects.

Exelixis excels in Q2 with cabozantinib driving revenue growth

Exelixis delivered a strong Q2 performance driven by cabozantinib franchise. Despite challenges in a competitive landscape, the company's focus on pipeline assets and commercial success presents growth opportunities. With increased revenue guidance and strategic initiatives, Exelixis is poised for continued success.

Exelixis excels in Q3 2024 with revenue growth and increased guidance

Exelixis delivered a strong performance in Q3 2024, marked by revenue growth, profitability, and increased guidance for the full year. The company's financial stability, strategic focus on oncology, and strong cash position provide a solid foundation for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from a post-hoc analysis of the phase 3 CheckMate -9ER trial demonstrating that CABOMETYX® (cabozantinib) in combination with Bristol Myers Squibb's OPDIVO® (nivolumab) resulted in a statistically significant and clinically meaningful increase in quality-adjusted survival compared with sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC). The quality-adjusted time without symp

Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from a post-hoc exploratory analysis demonstrating that the efficacy benefits seen in the phase 3 CheckMate -9ER trial with CABOMETYX® (cabozantinib) in combination with Bristol Myers Squibb's OPDIVO® (nivolumab) compared with sunitinib as a first-line treatment for advanced renal cell carcinoma (RCC) were observed across analyzed subgroups, including those based on International Metastatic Renal Cell Carcin

Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced promising phase 2 results for CABOMETYX® (cabozantinib) in combination with Bristol Myers Squibb's OPDIVO® (nivolumab) in patients with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC) from an investigator-sponsored trial. The combination regimen showed promising efficacy and an acceptable safety profile in patients with metastatic nccRCC with papillary, unclassified or translocation-associated hi

Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following virtual investor conferences in June: William Blair 41st Annual Growth Stock Conference: Exelixis is scheduled to present at 5:00pm EDT / 2:00pm PDT on Wednesday, June 2, 2021. Goldman Sachs 42nd Annual Global Healthcare Conference: Exelixis is scheduled to present at 1:20pm EDT / 10:20am PDT on Wednesday, June 9, 2021.

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June

EverBank Financial

Alphabet

Patient investors should make bank from this diverse collection of high-quality businesses.

The Best Stocks to Invest $3,000 in Right Now

Exelixis (EXEL) announces encouraging results from the cohort 6 of a phase Ib study of Cabometyx in combination with Tecentriq.

Exelixis (EXEL) Reports Encouraging Data From Prostate Cancer Study

Roche Holding AG

Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination with Roche's Tecentriq (atezolizumab) in patients with locally advanced or metastatic solid tumors. Cohort 6 included patients with metastatic castration-resistant prostate cancer, who were previously treated with enzalutamide or abiraterone acetate.

Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from the metastatic castration-resistant prostate cancer (CRPC) cohort 6 of COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cohort 6 included patients with metastatic CRPC who had been previously treated with enzalutamide and/or abiraterone acetate. Upon enrollment, patients had to have measurable disea

Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

Revenue growth will probably accelerate soon, but it might not be enough.

Is Exelixis a Buy?

DermTech Inc

Teladoc

All three healthcare stocks could have solid growth prospects.

What Investors Should Look for With Exelixis, DermTech, and Teladoc Health

BioNTech SE

Foot Locker

With the trading day about halfway over, the markets were somewhat mixed on Tuesday.

BioNTech, Exelixis, Foot Locker and More Tuesday Afternoon Analyst Calls

Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.

Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat

Exelixis (EXEL) CEO Mike Morrissey on Q1 2021 Results - Earnings Call Transcript

Exelixis (EXEL) delivered earnings and revenue surprises of -100.00% and 0.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Reports Break-Even Earnings for Q1

Shares of Exelixis (NASDAQ:EXEL) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 52.63% over the past year to $0.09, which beat the estimate of $0.03.

Exelixis: Q1 Earnings Insights

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. “The Exelixis team made significant progress across all components of our business in the first quarter of 2021, and delivered top-line revenue growth following the U.S. approval of CABOMETYX® in combination with OPDIVO® for

Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update

ALAMEDA, Calif. & TOULOUSE, France--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and GamaMabs Pharma SA today announced that they have entered into an agreement under which Exelixis will, upon the future closing of the asset purchase and subject to certain conditions to closing, acquire all rights, title and interest in GamaMabs' AMHR2 antibody technology. Exelixis will pay GamaMabs $5 million upon signing of the agreement, make additional payments upon completion of closing conditions, and m

Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma's First-in-Class Humanized Antibody Program Against a Novel Oncology Target

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will participate in fireside chats at the following virtual investor conferences in May: 7th Annual Truist Securities Life Sciences Summit: Exelixis is scheduled to present at 3:30pm EDT / 12:30pm PDT on Tuesday, May 4, 2021. BofA Securities 2021 Health Care Conference: Exelixis is scheduled to present at 2:00pm EDT / 11:00am PDT

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May

Bristol-Myers

Vertex Pharmaceuticals

They're generating revenue now -- and more is on the way.

3 Top Biotech Picks to Buy and Hold for the Next 10 Years

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the webcast link, log onto www.exelixis.com and proceed to the

Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021

Zoom Video

These fast-paced companies are on the leading edge of innovation.

3 Growth Stocks That'll Make You Richer in Q2 (and Beyond)

The FDA accepts Exelixis' (EXEL) IND for XB002 in patients with advanced solid tumors and a phase I study is expected to start in the second quarter.

Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with advanced solid tumors. As a next-generation tissue factor-targeting antibody-drug conjugate (ADC), XB002 has the potential for an improved therapeutic index and may provide a favorable safety pr

Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors

Exelixis' (EXEL) partner Ipsen secures an approval from the regulatory body in Europe for the combination of Cabomteyx and Opdivo to treat first-line RCC.

Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for advanced renal cell carcinoma (RCC). This approval allows for the marketing of CABOMETYX in combination with OPDIVO in this indication in all 27 member states of the European Union, Norway, Iceland and Liechtenstein. “We are excited that CABOMETYX i

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

News for Exelixis Stock (EXEL)